Published in Br J Cancer on June 01, 1995
Influence of thymidylate synthase and p53 protein expression on clinical outcome in patients with colorectal cancer. Int J Colorectal Dis (2004) 0.79
Enhancement of 5-fluorouracil-induced cytotoxicity by leucovorin in 5-fluorouracil-resistant gastric cancer cells with upregulated expression of thymidylate synthase. Gastric Cancer (2013) 0.79
Targeting nuclear thymidylate biosynthesis. Mol Aspects Med (2016) 0.75
Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group study. Invest New Drugs (2002) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst (1973) 10.64
The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol (1993) 4.09
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol (1989) 3.44
Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochim Biophys Acta (1977) 2.48
Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry (1974) 2.42
A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol (1988) 2.14
Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol (1986) 1.98
A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol (1987) 1.75
Characteristics of cell lines established from human colorectal carcinoma. Cancer Res (1987) 1.69
Chemotherapy of gastrointestinal cancer. N Engl J Med (1978) 1.56
Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. Cancer Res (1991) 1.27
Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma. Mol Pharmacol (1993) 1.23
Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol (1989) 1.14
Cytotoxicity of 5-fluoro-2'-deoxyuridine: requirement for reduced folate cofactors and antagonism by methotrexate. Proc Natl Acad Sci U S A (1978) 1.11
Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Cancer Res (1981) 1.09
Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil. Cancer Res (1984) 0.99
Immunological quantitation of thymidylate synthase-FdUMP-5,10-methylenetetrahydrofolate ternary complex with the monoclonal antibody TS 106. Anticancer Drugs (1993) 0.98
Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously. J Natl Cancer Inst (1991) 0.96
Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. J Clin Oncol (1988) 0.91
Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Cancer Res (1986) 0.90
Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines. J Natl Cancer Inst (1988) 0.88
Intracellular metabolism of 5-formyl tetrahydrofolate in human breast and colon cell lines. Cancer Res (1992) 0.87
Cytotoxicity of floxuridine and 5-fluorouracil in human T-lymphoblast leukemia cells: enhancement by leucovorin. Cancer Treat Rep (1987) 0.87
Schedule-dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid. Cancer Res (1991) 0.86
Thymidylate synthetase and 2'-deoxyuridylate form a tight complex in the presence of pteroyltriglutamate. J Biol Chem (1979) 0.85
Role of folylpolyglutamates in biochemical modulation of fluoropyrimidines by leucovorin. Cancer Res (1991) 0.81
Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study. J Natl Cancer Inst (1992) 0.80
Molecular mechanisms of drug resistance. J Pathol (2005) 4.60
Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res (1995) 3.04
Somnolence after prophylactic cranial irradiation in children with acute lymphoblastic leukaemia. Br Med J (1973) 2.94
Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci U S A (1991) 2.67
Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest (1985) 2.06
HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene (2007) 2.00
Identification of an RNA binding site for human thymidylate synthase. Proc Natl Acad Sci U S A (1993) 1.94
The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol (1994) 1.94
Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent. J Exp Med (1987) 1.70
c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene (2006) 1.66
Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci U S A (1985) 1.65
NIH conference. Pneumocystis pneumonia: from bench to clinic. Ann Intern Med (1989) 1.58
Cortactin underpins CD44-promoted invasion and adhesion of breast cancer cells to bone marrow endothelial cells. Oncogene (2006) 1.56
Mechanism of pyrimethamine resistance in recent isolates of Plasmodium falciparum. Antimicrob Agents Chemother (1984) 1.52
Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res (1992) 1.50
Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro. Biochemistry (1993) 1.49
Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem (1985) 1.49
Cell cycle regulation of the G0/G1 transition in 5-fluorouracil-sensitive and -resistant human colon cancer cell lines. Cancer J (2001) 1.47
Characterization of de novo folate synthesis in Pneumocystis carinii and Toxoplasma gondii: potential for screening therapeutic agents. J Infect Dis (1989) 1.44
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol (2007) 1.44
Study of cardiac rhythm in healthy newborn infants. Br Heart J (1980) 1.43
Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex. Mol Cell Biol (1999) 1.40
Chemoresistance in solid tumours. Ann Oncol (2006) 1.39
Combined test of anterior pituitary function in children. Arch Dis Child (1978) 1.34
Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res (1996) 1.31
Potent effect of trimetrexate, a lipid-soluble antifolate, on Toxoplasma gondii. J Infect Dis (1987) 1.29
Isolation and mapping of a human septin gene to a region on chromosome 17q, commonly deleted in sporadic epithelial ovarian tumors. Cancer Res (2000) 1.28
Anti-apoptotic mechanisms of drug resistance in cancer. Curr Cancer Drug Targets (2009) 1.27
Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. Cancer Res (1991) 1.27
Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol (1995) 1.27
Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma. Mol Pharmacol (1993) 1.23
Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate. J Clin Invest (1987) 1.22
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer (2006) 1.22
Controlling elements in the mouse. IV. Evidence of non-random X-inactivation. Genet Res (1981) 1.21
Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate. Antimicrob Agents Chemother (1988) 1.19
BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene (2001) 1.18
Characterization of a cis-acting regulatory element in the protein coding region of thymidylate synthase mRNA. Nucleic Acids Res (2000) 1.18
The effect of methotrexate on intracellular folate pools in human MCF-7 breast cancer cells. Evidence for direct inhibition of purine synthesis. J Biol Chem (1986) 1.17
Thymidylate synthase and drug resistance. Eur J Cancer (1995) 1.17
Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus. Cancer (1995) 1.16
A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J Immunother (1999) 1.16
24-hour electrocardiographic study of heart rate and rhythm patterns in population of healthy children. Br Heart J (1981) 1.16
Genomic organization, complex splicing pattern and expression of a human septin gene on chromosome 17q25.3. Oncogene (2001) 1.14
Methylation analysis of a marsupial X-linked CpG island by bisulfite genomic sequencing. Genome Res (1996) 1.14
Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol (1989) 1.14
LINE-I element insertion at the t(11;22) translocation breakpoint of a desmoplastic small round cell tumor. Genes Chromosomes Cancer (1997) 1.14
The role of thymidylate synthase as an RNA binding protein. Bioessays (1996) 1.11
Identification of a thymidylate synthase ribonucleoprotein complex in human colon cancer cells. Mol Cell Biol (1994) 1.11
Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer (2000) 1.11
p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin Cancer Res (1998) 1.10
Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen. Clin Cancer Res (2001) 1.09
24-hour tape recordings of ECG and respiration in the newborn infant with findings related to sudden death and unexplained brain damage in infancy. Arch Dis Child (1980) 1.09
Efficacy of trimetrexate, a potent lipid-soluble antifolate, in the treatment of rodent Pneumocystis carinii pneumonia. Am J Trop Med Hyg (1988) 1.08
Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol (1997) 1.08
Frequency and outcome of disorders of cardiac rhythm and conduction in a population of newborn infants. Pediatrics (1981) 1.08
Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst (1997) 1.07
Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res (1990) 1.06
Comparative genomic hybridization analysis of chromosomal alterations induced by the development of resistance to thymidylate synthase inhibitors. Cancer Res (1998) 1.06
Mycoplasma pneumoniae infections in children. Arch Dis Child (1978) 1.06
Enhanced cytotoxicity with interleukin-1 alpha and 5-fluorouracil in HCT116 colon cancer cells. Oncol Res (1994) 1.04
Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Mol Pharmacol (1991) 1.03
Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells. Oncogene (2008) 1.03
Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. Clin Cancer Res (2000) 1.03
The role of thymidylate synthase in cellular regulation. Adv Enzyme Regul (1996) 1.02
Prospective study of fetal heart rate and rhythm patterns. Arch Dis Child (1980) 1.02
Physical interaction between p53 and primary response gene Egr-1. Int J Oncol (2001) 1.02
Thymidylate synthase binds to c-myc RNA in human colon cancer cells and in vitro. Mol Cell Biol (1995) 1.02
RAN GTPase is an effector of the invasive/metastatic phenotype induced by osteopontin. Oncogene (2008) 1.02
Characterization of a specific interaction between Escherichia coli thymidylate synthase and Escherichia coli thymidylate synthase mRNA. Nucleic Acids Res (1995) 1.01
Molecular heterogeneity and function of EWS-WT1 fusion transcripts in desmoplastic small round cell tumors. Clin Cancer Res (2000) 1.01
Myelosuppressive effect of colaspase (L-asparaginase) in initial treatment of acute lymphoblastic leukaemia. Br Med J (1974) 1.01
Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res (1998) 1.01
Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis. Cell Death Differ (2012) 1.00
T-box 2 represses NDRG1 through an EGR1-dependent mechanism to drive the proliferation of breast cancer cells. Oncogene (2010) 1.00
Immunological quantitation of thymidylate synthase-FdUMP-5,10-methylenetetrahydrofolate ternary complex with the monoclonal antibody TS 106. Anticancer Drugs (1993) 0.98
Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies. Clin Cancer Res (2001) 0.98
The effect of reducing reagents on binding of thymidylate synthase protein to thymidylate synthase messenger RNA. J Biol Chem (1994) 0.98
The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study. Br J Cancer (2011) 0.97
Characterization of dihydrofolate reductase of Pneumocystis carinii and Toxoplasma gondii. Exp Parasitol (1990) 0.97
The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue. Br J Cancer (2011) 0.97
Bleeding diathesis in multiple myeloma. J Hematother Stem Cell Res (2001) 0.97
Identification of in vivo target RNA sequences bound by thymidylate synthase. Nucleic Acids Res (1996) 0.95
Folate cycle kinetics in human breast cancer cells. J Biol Chem (1989) 0.95
Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin Cancer Res (2000) 0.94
Stch encodes the 'ATPase core' of a microsomal stress 70 protein. EMBO J (1994) 0.94
Investigation of systemic folate status, impact of alcohol intake and levels of DNA damage in mononuclear cells of breast cancer patients. Br J Cancer (2005) 0.94
Increased expression of the RIalpha subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer. Br J Cancer (1999) 0.94
Molecular and biochemical markers in colorectal cancer. Ann Oncol (2002) 0.94